Announced details
Healthcare; corporate presentations for institutional investors
Consolidated Subsidiaries
A consolidated subsidiary of the Company. Other company information: Not disclosed
New York, United States (conference venue)
Does not involve the occurrence of new material information under Japan's timely disclosure rules
The company does not address Contract Value / Offering price.
Form 8-K and Exhibit 99.1 filed with the U.S. Securities and Exchange Commission (SEC), and Gyre's investor relations website
| Item | Details |
|---|---|
| Counterparty | Gyre Therapeutics, Inc. |
| Counterparty overview | A consolidated subsidiary of the Company. Other company information: Not disclosed |
| Relationship with the Company | Consolidated Subsidiaries |
| Launch date | 3 June 2026 (the date of participation in a healthcare conference for institutional investors to be held in New York; as of the time of this announcement, the conference is scheduled to take place) |
| Applicable area | Healthcare; corporate presentations for institutional investors |
| Location | New York, United States (conference venue) |
| Impact on Business Performance | Does not involve the occurrence of new material information under Japan's timely disclosure rules |
| Source | Form 8-K and Exhibit 99.1 filed with the U.S. Securities and Exchange Commission (SEC), and Gyre's investor relations website |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To eliminate information asymmetry in the capital markets of Japan and the United States and ensure thorough fair disclosure.